10-K: Lantern Pharma Reports 2025 Losses, Seeks Funding Amid Clinical Progress

Lantern Pharma, an AI-driven oncology firm, reported continued net losses in 2025 and faces substantial doubt about its ability to continue as a going concern, despite advancing multiple drug candidates and expanding its AI platform.

Summary

• Lantern Pharma incurred a net loss of approximately $17.1 million for the year ended December 31, 2025, an improvement from $20.8 million in 2024.
• Operating expenses decreased by 29% to $17.98 million in 2025 from $22.22 million in 2024, primarily due to a $4.03 million reduction in research studies and materials.
• The company's cash, cash equivalents, and marketable securities are projected to fund operations until late July to mid-September 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern without obtaining significant additional funding.
• The RADR AI platform has expanded to over 200 billion oncology-focused data points and introduced new modules for ADC development, combination regimen prediction, and blood-brain barrier permeability.
• In January 2026, Lantern Pharma launched withZeta.ai, a generative AI platform for rare cancer research and drug development.
• LP-300 (HARMONIC trial, Phase 2 NSCLC) showed an 86% clinical benefit rate and 43% objective response rate in the safety lead-in cohort, with one patient achieving a durable complete response for nearly two years.
• LP-184 (Phase 1a) completed enrollment with 63 patients, demonstrating a manageable safety profile and tumor shrinkage in 22% of evaluable patients, with durable disease control in 3 patients.
• FDA cleared two new Phase 1b/2 INDs for LP-184 in 2025, targeting recurrent triple-negative breast cancer (TNBC) and biomarker-defined non-small cell lung cancer (NSCLC) with KEAP1/STK11 mutations.
• LP-284 (Phase 1) is advancing, with a complete metabolic response observed in a heavily pre-treated DLBCL patient after two cycles.
• The company holds over 200 active patents and patent applications across 20 patent families for its drug candidates and AI platform.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' warning and the critical need for substantial additional funding within a short timeframe, overshadowing positive clinical progress and AI platform advancements.

Positives

• Net loss decreased to $17.1 million in 2025 from $20.8 million in 2024, indicating improved financial performance year-over-year.
• Operating expenses decreased by 29% in 2025, primarily due to reduced research and development costs.
• The RADR AI platform has significantly expanded to over 200 billion data points and 200+ machine learning algorithms, enhancing drug discovery capabilities.
• Launch of withZeta.ai in January 2026 provides a generative AI platform for accelerating rare cancer research and drug development.
• LP-300's HARMONIC Phase 2 trial safety lead-in showed encouraging clinical efficacy with an 86% clinical benefit rate and a 43% objective response rate, including a durable complete response in one patient.
• LP-184 Phase 1a trial completed enrollment, demonstrating a manageable safety profile and preliminary anti-tumor signals, with durable disease control in some patients.
• FDA cleared two new Phase 1b/2 INDs for LP-184 in 2025, expanding clinical pipeline opportunities in TNBC and NSCLC, targeting a market opportunity estimated to exceed $2 billion annually for NSCLC.
• LP-184 received FDA Fast Track Designations for GBM and TNBC, and multiple Orphan Drug and Rare Pediatric Disease Designations, potentially accelerating development and offering market exclusivity benefits.
• LP-284 achieved a complete metabolic response in a heavily pre-treated DLBCL patient in its Phase 1 trial, highlighting its potential in aggressive hematological cancers.
• LP-284 has received multiple Orphan Drug Designations and composition of matter patents in key global markets.
• The company maintains an extensive intellectual property portfolio with over 200 active patents and patent applications across 20 patent families.

Negatives

• The company has incurred significant operating losses since inception and anticipates continued substantial losses for the foreseeable future, with no revenue generated other than from a prior research grant.
• Substantial doubt exists about the company's ability to continue as a going concern without obtaining significant additional funding.
• Existing cash, cash equivalents, and marketable securities are only expected to fund operating expenses and capital expenditure requirements until late July to mid-September 2026, necessitating substantial additional funding in the near future.
• Interest income decreased by approximately $304,000 in 2025 due to reductions in marketable securities held.
• Other income, net, decreased by approximately $272,000 in 2025, primarily due to decreases in dividend and other investment income.
• Enrollment of patients in the LP-300 HARMONIC study in the U.S. has been challenging, requiring expansion to East Asian countries.
• The company has limited experience in drug discovery and development and has not yet received regulatory approval for any drug candidate.
• The strategy to 'rescue' previously failed drug candidates carries inherent risks, including potentially shorter patent terms and skepticism from potential partners.
• The company is highly dependent on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs), introducing risks related to compliance, quality, and timely performance.
• The stock price has been volatile and often thinly traded, which may impair stockholders' ability to sell shares.

Risks

• Substantial additional funding will be needed in the near future, and failure to raise capital could force delays, reductions, or elimination of drug development programs or commercialization efforts.
• The company has a limited operating history and has never generated revenues other than from research grants, making it difficult to evaluate future viability and success.
• Significant operating losses have been incurred since inception and are anticipated to continue, with no assurance of achieving or maintaining profitability.
• The RADR platform may fail to help discover and develop additional potential drug candidates, or identified compounds may not demonstrate efficacy, safety, or tolerability.
• The business strategy to rescue previously failed drug candidates may not be successful, and important safety and efficacy issues remain to be resolved.
• Dependence on enrollment of patients with specific genomic or biomarker signatures in clinical trials, and inability to enroll sufficient patients, could adversely affect development efforts.
• Delays in clinical testing could result in increased costs and delay the ability to generate revenue.
• Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder timely development, approval, or commercialization.
• Changes in priorities at the FDA and other government agencies could hinder the ability to develop and commercialize product candidates.
• Drug candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-marketing.
• Failure to comply with existing regulations could harm reputation and operating results.
• Inability to obtain and retain sufficient clinical trial liability insurance at an acceptable cost could prevent or inhibit clinical trials.
• Even if preclinical studies and clinical trials are successful, commercialization of drug candidates may not be successful.
• If drugs do not gain market acceptance, the business will suffer due to inability to fund future operations.
• Failure to obtain marketing approval in foreign jurisdictions would prevent drug candidates from being marketed abroad.
• Approved drug candidates could be subject to post-marketing restrictions or withdrawal from the market, with substantial penalties for non-compliance or unanticipated problems.
• Healthcare reform measures could hinder or prevent commercial success of drug candidates.
• Governments outside of the United States tend to impose strict price controls, which may adversely affect revenues.
• Reliance on third parties to conduct preclinical studies and clinical trials poses risks if they do not perform contractual duties or meet deadlines.
• Substantial dependence on third parties for manufacturing clinical and commercial supplies of drug candidates, with risks of delays or reduced profitability if manufacturers fail to obtain approval or provide sufficient quantities.
• Inability of the company or third-party manufacturers to successfully scale-up manufacturing in sufficient quality and quantity could delay or prevent development and commercialization.
• Reliance on statistical, market, and industry data from third parties that have not been independently verified.
• Involvement in lawsuits to protect or enforce patent or other intellectual property rights could be expensive, time-consuming, and unsuccessful.
• Claims by third parties asserting infringement, misappropriation, or wrongful use of their intellectual property rights could have a material adverse effect.
• Stock price has been volatile and often thinly traded, impairing the ability to sell shares.
• Future sales and issuances of common stock could result in additional dilution of percentage ownership and cause share price to fall.
• Broad discretion in the use of financial resources, which may not be used effectively.
• Acquisition of other companies or technologies could divert management's attention, result in dilution, and disrupt operations.
• Market and economic conditions, including inflation and changes in interest rates, may negatively impact business.
• Intellectual property rights do not necessarily address all potential threats, and patent protection could be reduced or eliminated for non-compliance.
• Failure to comply with obligations in intellectual property licenses and funding arrangements could lead to loss of important rights.
• Dependence on senior management team, and loss of key employees or inability to attract/retain skilled employees could adversely affect business.
• Employee misconduct or improper activities, including noncompliance with regulatory standards and insider trading, could lead to criminal penalties, fines, or reputational harm.
• Business interruptions (e.g., natural disasters, cyber-attacks) could adversely affect future operations, revenues, and financial conditions.
• Disruptions to information technology systems, including future cyber-attacks and security breaches, and the costs of maintaining secure systems could negatively affect business.
• Unfavorable geopolitical and macroeconomic developments (e.g., conflicts in Ukraine, Gaza, Iran, inflation, bank failures) could adversely affect business, financial condition, or results of operations.
• Failure to successfully acquire, develop, and market additional drug candidates could impair ability to grow.
• Financial reporting obligations of being a public company require well-defined disclosure and financial controls that are expensive and time-consuming.
• Failure to comply with Sarbanes-Oxley Act rules related to accounting controls and procedures could lead to stock price decline and difficulty raising capital.
• Comprehensive tax reform bills could adversely affect business and financial condition.

Future Outlook

Lantern Pharma anticipates continued substantial operating losses and will require significant additional funding in the near future to support its drug development programs and commercialization efforts. The company plans to strategically evaluate its programs for internal development or out-licensing to maximize commercial opportunities. It also expects to introduce its proprietary AI platforms as a potential source of revenue in 2026 through subscriptions, access, and services for biopharma companies and researchers. The company aims to expand its pipeline by identifying new drug candidates and pursuing combination therapies, while continuously advancing its AI algorithms and intellectual property portfolio.

Management Comments

• Our dual approach to both develop de-novo, biomarker-guided drug candidates and rescue historical drug-candidates by leveraging A.I., recent advances in genomics, computational biology and cloud computing is emblematic of a new era in drug development that is being driven by data-intensive approaches meant to de-risk development and accelerate the clinical trial process.
• On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-$2.5 million per program.
• We believe our existing cash, cash equivalents, and marketable securities on hand as of the date of this report will enable us to fund our operating expenses and capital expenditure requirements until at least approximately late July 2026 to mid September 2026.
• We will need substantial additional funding in the near future, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development programs or commercialization efforts.

Industry Context

StockSavvy.ai notes that Lantern Pharma operates at the intersection of the rapidly evolving biotechnology and AI drug development industries. The company's focus on 'drug rescue' and de-novo development, powered by its RADR platform, aligns with the broader industry shift towards data-intensive approaches to de-risk and accelerate drug development. This trend is driven by increasing R&D costs and the need for more personalized, efficient therapies, with biopharma AI spending projected to reach $3 billion by 2025. Lantern Pharma's strategy to leverage AI for biomarker identification and patient stratification positions it to potentially capitalize on this shift, although it faces intense competition from both established pharmaceutical giants and other AI-focused drug developers like AbCellera, Atomwise, and Recursion Pharmaceuticals.

Comparison to Industry Standards

• Lantern Pharma's average advancement of new drug programs from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-$2.5 million per program is significantly faster and more cost-effective than the estimated mean cost of $4.4 billion and lengthy timelines associated with traditional cancer drug development (DIA Global Forum, 2019; Targeted Oncology, 2023).
• The overall Phase 1-to-approval probability of success in oncology is estimated at just 3.3%, highlighting the high-risk nature of the industry, which Lantern Pharma aims to mitigate through its AI-driven approach.
• LP-300's retrospective subgroup analysis showing a 13.6-month improvement in overall survival (25.0 months vs. 13.2 months) in female never-smokers with NSCLC adenocarcinoma receiving paclitaxel/cisplatin and LP-300 (p-value 0.0477; HR=0.579) compares favorably to the typical 7-12 month median overall survival for stage IV NSCLC patients with conventional treatments.
• The observed complete metabolic response for LP-284 in a heavily pre-treated DLBCL patient who failed CAR-T cell therapy is notable, as relapsed/refractory DLBCL patients have poor prognoses with reported median survival of 8.6 to 16 months after failing frontline chemo-immunotherapies.
• LP-184's preclinical data showing 107%-132% tumor growth inhibition with complete tumor regression in TNBC PDX models, and 102% TGI in H460 (KEAP1 and STK11 double mutant) human NSCLC cell line derived xenograft tumor model, suggests strong efficacy compared to existing therapies that often face resistance.
• STAR-001's (LP-184) ability to cross the blood-brain barrier and prolong median overall survival in an orthotopic GBM xenograft model (42 days vs. 33 days for control, p < 0.0001) and its potential effectiveness regardless of MGMT status offers a needed alternative to temozolomide (TMZ), which is ineffective in up to 50% of GBM cancers due to MGMT overexpression.

Legal Proceedings

• Not currently a party to any legal proceedings, and not aware of any pending or threatened litigation that could have a material adverse effect on the business, operating results or financial condition.

Related Party Transactions

• Mr. Margrave, Chief Financial Officer and Secretary, formerly served as President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik Pharmaceuticals, Inc. and has a minority ownership interest in BioNumerik, from which the company acquired LP-300 rights.
• Certain affiliates of Bios Partners beneficially own greater than 10% of the company's common stock and also hold substantial beneficial ownership interests in Actuate Therapeutics, Inc., with whom the company has a collaboration agreement.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity offerings due to the company's need for substantial additional funding.
• Shareholders are exposed to high investment risk due to the company's limited operating history, consistent net losses, and 'going concern' warning.
• Patients with advanced cancers, particularly NSCLC, TNBC, GBM, and hematological cancers, could potentially benefit from the company's drug candidates if they successfully navigate clinical trials and regulatory approval.
• Employees face uncertainty due to the company's financial condition and the need for ongoing capital raises, although the company emphasizes fostering a strong culture and competitive compensation.
• Third-party contractors and suppliers (CMOs, CROs) are critical to the company's operations, and their performance directly impacts drug development timelines and costs.
• Regulatory bodies (FDA, EMA) are key stakeholders as their approvals are essential for commercialization, and their changing priorities or scrutiny could impact the company's development path.

Next Steps

• Obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, licensing arrangements, or other sources.
• Advance and optimize development plans for multiple future LP-184 clinical studies, including FDA-cleared Phase 1b/2 trials in TNBC and biomarker-defined NSCLC.
• Continue advancing LP-284 in its Phase 1 clinical trial and plan for Phase 1b enrollment of up to 40 additional patients with Relapsed or Refractory DLBCL and MCL.
• Conduct a Type C meeting with the FDA in mid-May 2026 to seek feedback and concurrence on proposed protocol amendments for the LP-300 HARMONIC study.
• Commercially release select RADR AI modules to the broader research and drug development community to foster collaborative, open-source innovation in oncology.
• Evaluate multiple partnership and commercialization models for AI platforms (withZeta.ai and RADR modules) through subscriptions, access, and services for biopharma companies, researchers, and drug developers in 2026.
• Pursue existing indications for LP-300, LP-184, LP-284, the ADC program, and other product candidates, leveraging the RADR platform to refine trial design and biomarker signatures.
• Expand the pipeline by identifying new drug candidates that have been abandoned or failed in late-stage clinical trials, and have potential for precision medicine approaches.
• Identify and design potential combination therapy approaches for compounds using the RADR platform.
• Advance algorithms, methodologies, and models underlying the computational and machine learning platform to improve predictive power and develop additional capabilities.
• Pursue collaborations and partnerships with other biotech and pharma companies where AI and precision oncology expertise can de-risk or accelerate development programs.
• Continue to develop and patent intellectual property and advance the intellectual property portfolio.
• Evaluate, select, and launch additional clinical development programs.

Key Dates

Recommendation

The explicit 'going concern' warning from both management and the independent auditor, coupled with the stated need for 'substantial additional funding in the near future' and a limited cash runway until mid-2026, presents a significant and immediate financial risk. While there are positive clinical updates and advancements in the AI platform, these are early-stage developments that require considerable capital to progress. The high probability of further dilution from capital raises and the inherent unpredictability of drug development, especially for 'rescued' candidates, make the stock a high-risk investment with a strong likelihood of further downside in the short to medium term. A seasoned investor would likely divest or avoid new positions until the funding situation is resolved and a clear path to profitability is demonstrated.

Keywords

Oncology, Artificial Intelligence, Drug Discovery, Drug Development, Cancer Therapies, RADR Platform, LP-300, LP-184, LP-284, NSCLC, Triple Negative Breast Cancer, Glioblastoma, Hematological Cancers, Orphan Drug, Fast Track Designation, Biomarker-driven, Clinical Trials, Biotechnology, Pharmaceuticals, withZeta.ai, ADC Program, Going Concern